CytoLyt® Fixation Significantly Inhibits MIB1 Immunoreactivity, whereas Alternative Ki67 Clone 30-9 is not Susceptible to the Inhibition: Critical Diagnostic Implications

CytoLyt® fixation substantially inhibits MIB1 immunoreactivity and may present a diagnostic pitfall in certain tumors, especially small cell carcinoma. The Ki67 30-9 clone shows adequate performance and we strongly recommend it for laboratories utilizing CytoLyt® collection media.

Saved in:
Bibliographic Details
Published in:Cancer cytopathology 2019-08, Vol.127 (10), p.643-649
Main Authors: Buonocore, Darren J., Konno, Fumiko, Jungbluth, Achim A., Frosina, Denise, Fayad, Mariam, Edelweiss, Marcia, Lin, Oscar, Rekhtman, Natasha
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:CytoLyt® fixation substantially inhibits MIB1 immunoreactivity and may present a diagnostic pitfall in certain tumors, especially small cell carcinoma. The Ki67 30-9 clone shows adequate performance and we strongly recommend it for laboratories utilizing CytoLyt® collection media.
ISSN:1934-662X
1934-6638
DOI:10.1002/cncy.22170